ACTIV-3-Therapeutics for Inpatients with COVID- 19 ( TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial (vol 10, 2022)
LANCET RESPIRATORY MEDICINE（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要